Our results provided the direct evidence that NMDAR inhibition can prevent the overexpression of PACAP in an experimental model of migraine and support the idea that therapies aimed at the modulation of glutamatergic transmission, including the use of KYNA derivatives, may be of therapeutic value in migraine. This evidence concerns the gene ADCYAP1 and migraine disorder.